Evidence map›Paper›PMID 39786437›Full record

ArticleWorld journal of urology2025

Development and validation of nomograms and integrated software incorporating preoperative C-reactive protein level for prognostic prediction of nonmetastatic clear cell renal cell carcinoma: Results from the International Marker Consortium for Renal Cancer (INMARC) Registry.

Wei Chen, Hajime Tanaka, Masaki Kobayashi, Shohei Fukuda, Akinori Nakayama, Margaret F Meagher, Rachel Greenwald, Benjamin Schmeusser, Edouard Nicase, Yuma Waseda and 5 more

Abstract readValidation StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wei ChenDepartment of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.ORCID http://orcid.org/0000-0003-2275-4527
Hajime TanakaDepartment of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan. hjtauro@tmd.ac.jp.ORCID http://orcid.org/0000-0003-3632-2901
Masaki KobayashiDepartment of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.ORCID http://orcid.org/0000-0003-2738-9792
Shohei FukudaDepartment of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.ORCID http://orcid.org/0000-0003-2741-8338
Akinori NakayamaDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Margaret F MeagherDepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Rachel GreenwaldDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Benjamin SchmeusserDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Edouard NicaseDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Yuma WasedaDepartment of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.ORCID http://orcid.org/0000-0002-9319-1373
Soichiro YoshidaDepartment of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.ORCID http://orcid.org/0000-0003-2757-8083
Ithaar H DerweeshDepartment of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-8673-0711
Viraj A MasterDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7251-142X
Yasuhisa FujiiDepartment of Urology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.ORCID http://orcid.org/0000-0002-6761-3229
Kazutaka SaitoDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0002-7261-0188

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePreoperative C-reactive protein (CRP) is a valuable prognostic biomarker in nonmetastatic clear cell renal cell carcinoma (nmccRCC). Incorporation of CRP into prognostic models may improve the prediction of oncologic outcomes. Herein, we aimed to develop and validate prognostic nomograms and an integrated software incorporating preoperative CRP level in nmccRCC.

methodsAn international multi-institutional database was retrospectively analyzed for nmccRCC patients undergoing surgery. A total of 2284 patients were enrolled and randomly allocated to training (n = 1599, 70%) and validation (n= 685, 30%) cohorts. Nomograms predicting overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were developed in the training cohort using multivariable Cox regression, including preoperative CRP levels and other clinical factors. An integrated software was also created. The validation cohort was used to assess the performance of these nomograms.

resultsFollowing a median follow-up of 5.9 years, 318 (13.92%) patients died of any cause, 109 (4.77%) died of renal cancer, and 282 (12.35%) developed recurrence. The median (interquartile range) preoperative CRP level was 1.90 (0.80-5.68) mg/L. A high CRP level was independently associated with worse OS, CSS, and RFS. The nomograms and integrated software incorporating CRP significantly improved prediction accuracy compared with CRP alone. The C-indices for nomograms were 0.74 (95%CI, 0.69-0.80) for OS, 0.87 (0.82-0.93) for CSS, and 0.77 (0.71-0.82) for RFS in the validation cohort. Acceptable calibration was demonstrated at 12/36/60 months for OS, CSS, and RFS.

conclusionsThe prognostic nomograms and the user-friendly integrated software incorporating preoperative CRP level may facilitate individualized risk stratification and treatment planning for patients with nmccRCC.

Indexed as

Carcinoma, Renal CellC-Reactive ProteinKidney NeoplasmsNomogramsSoftwareAgedFemaleHumansMaleMiddle AgedPredictive Value of TestsPreoperative PeriodPrognosisRegistriesRetrospective StudiesSurvival RateC-Reactive ProteinINMARCNomogramsPrediction modelPrognosisRenal cell carcinoma

Identifiers

PMID39786437

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.